Alberto Orfao

List of Publications by Year in descending order

238 papers	16,895 citations	18465 62 h-index	18115 120 g-index
244 all docs	244 docs citations	244 times ranked	16236 citing authors

#	Article	IF	Citations
1	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	5.1	1,866
2	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	1.6	766
3	Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. International Archives of Allergy and Immunology, 2012, 157, 215-225.	0.9	513
4	KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood, 2006, 108, 2366-2372.	0.6	447
5	Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood, 2008, 112, 4017-4023.	0.6	425
6	Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood, 2015, 125, 3996-4009.	0.6	410
7	Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood, 2017, 129, 347-357.	0.6	323
8	Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood, 2001, 98, 1746-1751.	0.6	316
9	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. Journal of Allergy and Clinical Immunology, 2016, 137, 35-45.	1.5	289
10	New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood, 2015, 125, 3059-3068.	0.6	256
11	Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. Journal of Allergy and Clinical Immunology, 2009, 124, 514-521.	1.5	252
12	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. Journal of Clinical Oncology, 2017, 35, 2900-2910.	0.8	248
13	Indolent Systemic Mast Cell Disease in Adults: Immunophenotypic Characterization of Bone Marrow Mast Cells and Its Diagnostic Implications. Blood, 1998, 91, 2731-2736.	0.6	232
14	Tumor infiltrating immune cells in gliomas and meningiomas. Brain, Behavior, and Immunity, 2016, 53, 1-15.	2.0	228
15	Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. Journal of Allergy and Clinical Immunology, 2018, 141, 2208-2219.e16.	1.5	217
16	Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica, 2010, 95, 1016-1020.	1.7	210
17	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Research, 2017, 77, 1261-1270.	0.4	210
18	Recent advances in the understanding of mastocytosis: the role of KIT mutations. British Journal of Haematology, 2007, 138, 12-30.	1.2	205

#	Article	IF	Citations
19	Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. Journal of Clinical Oncology, 2011, 29, 1627-1633.	0.8	202
20	Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy. Journal of Clinical Oncology, 2008, 26, 2737-2744.	0.8	193
21	Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry. Journal of Clinical Oncology, 2009, 27, 1462-1469.	0.8	189
22	Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for <scp>MRD</scp> detection in multiple myeloma. Cytometry Part B - Clinical Cytometry, 2016, 90, 61-72.	0.7	177
23	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. Journal of Clinical Oncology, 2020, 38, 784-792.	0.8	175
24	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1125-1133.e1.	2.0	150
25	Quality assessment program for <scp>E</scp>uro<scp>F</scp>low protocols: Summary results of fourâ€year (2010â€“2013) quality assurance rounds. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 145-156.	1.1	144
26	Molecular and Genomic Alterations in Glioblastoma Multiforme. American Journal of Pathology, 2015, 185, 1820-1833.	1.9	141
27	Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood, 2002, 99, 1853-1856.	0.6	140
28	Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica, 2005, 90, 1365-72.	1.7	135
29	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica, 2013, 98, 79-86.	1.7	132
30	Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood, 2013, 122, 3591-3598.	0.6	131
31	Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). , 2004, 58B, 1-8.		130
32	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood, 2016, 127, 3165-3174.	0.6	129
33	Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. Journal of Allergy and Clinical Immunology, 2010, 125, 719-726.e4.	1.5	128
34	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere, 2021, 5, e646.	1.2	128
35	Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leukemia Research, 2001, 25, 563-570.	0.4	124
36	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood, 2013, 121, 2393-2401.	0.6	122

#	Article	IF	Citations
37	Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends in Biotechnology, 2013, 31, 415-425.	4.9	119
38	Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis showsÂunique features versus other indolent SM. Journal of Allergy and Clinical Immunology, 2014, 133, 520-528.e5.	1.5	118
39	Expression of the c-kit (CD117) Molecule in Normal and Malignant Hematopoiesis. Leukemia and Lymphoma, 1998, 30, 459-466.	0.6	113
40	Immunophenotypic Analysis of the TCR-VÎ² Repertoire in 98 Persistent Expansions of CD3+/TCR-Î±Î²+ Large Granular Lymphocytes. American Journal of Pathology, 2001, 159, 1861-1868.	1.9	113
41	Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry Part B - Clinical Cytometry, 2016, 90, 26-30.	0.7	108
42	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. Theranostics, 2020, 10, 10743-10768.	4.6	107
43	TCRÎ±Î²+/CD4+ Large Granular Lymphocytosis. American Journal of Pathology, 2003, 163, 763-771.	1.9	104
44	Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica, 2014, 99, 1410-1420.	1.7	103
45	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematology,the, 2019, 6, e638-e649.	2.2	101
46	The EuroFlow PID Orientation Tube for Flow Cytometric Diagnostic Screening of Primary Immunodeficiencies of the Lymphoid System. Frontiers in Immunology, 2019, 10, 246.	2.2	100
47	Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica, 2009, 94, 1599-1602.	1.7	92
48	Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Modern Pathology, 2015, 28, 1138-1149.	2.9	88
49	Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget, 2017, 8, 68950-68963.	0.8	83
50	Genomic characterization of liver metastases from colorectal cancer patients. Oncotarget, 2016, 7, 72908-72922.	0.8	83
51	MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. Journal of Clinical Oncology, 2019, 37, 2846-2856.	0.8	82
52	Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 834-846.	1.1	81
53	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood, 2016, 127, 1896-1906.	0.6	81
54	The cellular origin and malignant transformation of WaldenstrÃ¶m macroglobulinemia. Blood, 2015, 125, 2370-2380.	0.6	80

#	Article	IF	Citations
55	Human IgE+ B cells are derived from T cellâ€“dependent and T cellâ€“independent pathways. Journal of Allergy and Clinical Immunology, 2014, 134, 688-697.e6.	1.5	79
56	<scp>CD</scp>30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology, 2013, 63, 780-787.	1.6	77
57	Chronic Alcoholism Is Associated With an Imbalanced Production of Th-1/Th-2 Cytokines by Peripheral Blood T Cells. Alcoholism: Clinical and Experimental Research, 1999, 23, 1306-1311.	1.4	76
58	Nanotechniques in proteomics: Protein microarrays and novel detection platforms. European Journal of Pharmaceutical Sciences, 2012, 45, 499-506.	1.9	75
59	Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. Haematologica, 2017, 102, 308-319.	1.7	74
60	Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. Journal of Allergy and Clinical Immunology, 2016, 137, 168-178.e1.	1.5	72
61	Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica, 2014, 99, 1228-1235.	1.7	69
62	PERISCOPE: road towards effective control of pertussis. Lancet Infectious Diseases, The, 2019, 19, e179-e186.	4.6	67
63	Immunophenotypic Identification and Characterization of Tumor Cells and Infiltrating Cell Populations in Meningiomas. American Journal of Pathology, 2012, 181, 1749-1761.	1.9	66
64	Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood, 2019, 134, 2218-2222.	0.6	66
65	Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget, 2016, 7, 10174-10181.	0.8	65
66	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer Journal, 2020, 10, 108.	2.8	60
67	Flow cytometry immunophenotyping of fine-needle aspiration specimens: utility in the diagnosis and classification of non-Hodgkin lymphomas. Histopathology, 2011, 58, 906-918.	1.6	59
68	Biomarker Discovery by Novel Sensors Based on Nanoproteomics Approaches. Sensors, 2012, 12, 2284-2308.	2.1	59
69	Complete Response After Imatinib Mesylate Therapy in a Patient With Well-Differentiated Systemic Mastocytosis. Journal of Clinical Oncology, 2012, 30, e126-e129.	0.8	59
70	Genetic/molecular alterations of meningiomas and the signaling pathways targeted. Oncotarget, 2015, 6, 10671-10688.	0.8	58
71	The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica, 2016, 101, 1451-1459.	1.7	55
72	Defects in memory B-cell and plasma cell subsets expressing different immunoglobulin-subclasses in patients with CVID and immunoglobulin subclass deficiencies. Journal of Allergy and Clinical Immunology, 2019, 144, 809-824.	1.5	55

#	Article	IF	Citations
73	Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Journal of Immunological Methods, 2000, 242, 53-65.	0.6	51
74	Contribution of Multiparameter Flow Cytometry Immunophenotyping to the Diagnostic Screening and Classification of Pediatric Cancer. PLoS ONE, 2013, 8, e55534.	1.1	48
75	B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. Blood, 2014, 124, 412-419.	0.6	48
76	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosomeâ€“negative adult lymphoblastic leukemia. Blood, 2021, 137, 1879-1894.	0.6	48
77	The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. Journal of Leukocyte Biology, 2015, 97, 49-59.	1.5	47
78	Utility of <scp>CD</scp>54, <scp>CD</scp>229, and <scp>CD</scp>319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry Part B - Clinical Cytometry, 2016, 90, 91-100.	0.7	47
79	CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica, 2011, 96, 328-332.	1.7	46
80	Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. Neuro-Oncology, 2010, 12, 991-1003.	0.6	45
81	Introduction to the diagnosis and classification of monocyticâ€lineage leukemias by flow cytometry. Cytometry Part B - Clinical Cytometry, 2017, 92, 218-227.	0.7	44
82	Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. Blood, 2019, 134, 456-468.	0.6	44
83	Fluorochrome choices for multi-color flow cytometry. Journal of Immunological Methods, 2019, 475, 112618.	0.6	43
84	EuroFlow-Based Flowcytometric Diagnostic Screening and Classification of Primary Immunodeficiencies of the Lymphoid System. Frontiers in Immunology, 2019, 10, 1271.	2.2	43
85	Immunophenotype of Bone Marrow Mast Cells in Indolent Systemic Mast Cell Disease in Adults. Leukemia and Lymphoma, 1999, 35, 227-235.	0.6	42
86	Impact of somatic and germline mutations on the outcome of systemic mastocytosis. Blood Advances, 2018, 2, 2814-2828.	2.5	42
87	Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia, 2020, 34, 589-603.	3.3	41
88	Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). Haematologica, 2017, 102, 235-245.	1.7	40
89	Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia. Journal of Immunological Methods, 2019, 475, 112429.	0.6	40
90	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 3151-3161.	0.8	40

#	Article	IF	Citations
91	Alterations in Tumor Necrosis Factor-alpha, Interferon-gamma, and Interleukin-6 Production by Natural Killer Cell-Enriched Peripheral Blood Mononuclear Cells in Chronic Alcoholism: Relationship with Liver Disease and Ethanol Intake. Alcoholism: Clinical and Experimental Research, 1997, 21, 1226-1231.	1.4	39
92	Molecular detection of minimal residual disease in multiple myeloma. British Journal of Haematology, 2018, 181, 11-26.	1.2	39
93	Age Distribution of Multiple Functionally Relevant Subsets of CD4+ T Cells in Human Blood Using a Standardized and Validated 14-Color EuroFlow Immune Monitoring Tube. Frontiers in Immunology, 2020, 11, 166.	2.2	39
94	Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer Journal, 2021, 11, 34.	2.8	39
95	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. Lancet Haematology,the, 2021, 8, e194-e204.	2.2	39
96	Amplified and Homozygously Deleted Genes in Glioblastoma: Impact on Gene Expression Levels. PLoS ONE, 2012, 7, e46088.	1.1	38
97	Immunophenotypic dissection of normal hematopoiesis. Journal of Immunological Methods, 2019, 475, 112684.	0.6	38
98	Self-assembled Protein Arrays from an Ornithodoros moubata Salivary Gland Expression Library. Journal of Proteome Research, 2012, 11, 5972-5982.	1.8	37
99	Detailed immunophenotyping of Bâ€cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection. British Journal of Haematology, 2017, 178, 257-266.	1.2	37
100	New technologies in cancer. Protein microarrays for biomarker discovery. Clinical and Translational Oncology, 2011, 13, 156-161.	1.2	36
101	EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets. Journal of Immunological Methods, 2019, 475, 112662.	0.6	35
102	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM Userâ€™s Guide for Daily Clinical Practice. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1999-2012.e6.	2.0	35
103	Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface. , 1998, 34, 223-228.		34
104	Gains of chromosome 22 by fluorescence in situ hybridization in the context of an hyperdiploid karyotype are associated with aggressive clinical features in meningioma patients. Cancer, 2001, 92, 377-385.	2.0	34
105	Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood, 2016, 127, 3035-3039.	0.6	34
106	Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. Haematologica, 2018, 103, 1198-1208.	1.7	34
107	STAT3 and STAT5B Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features. Cancers, 2020, 12, 3508.	1.7	34
108	Immunophenotype and TCR-Vî² repertoire of peripheral blood T-cells in acute infectious mononucleosis. Blood Cells, Molecules, and Diseases, 2003, 30, 1-12.	0.6	33

#	Article	IF	Citations
109	KIT D816Vâ€“mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression. Blood, 2016, 127, 761-768.	0.6	33
110	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3918-3928.	2.0	33
111	Distribution of subsets of blood monocytic cells throughout life. Journal of Allergy and Clinical Immunology, 2019, 144, 320-323.e6.	1.5	32
112	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Leukemia, 2021, 35, 2358-2370.	3.3	31
113	Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis. Journal of Allergy and Clinical Immunology, 2013, 131, 1213-1224.e4.	1.5	30
114	Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ SÃ©zary's syndrome. Haematologica, 2003, 88, 874-87.	1.7	30
115	Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. Leukemia Research, 2016, 40, 1-9.	0.4	29
116	Maturation-associated gene expression profiles during normal human bone marrow erythropoiesis. Cell Death Discovery, 2019, 5, 69.	2.0	29
117	Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examples. Journal of Immunological Methods, 2019, 475, 112287.	0.6	29
118	Abnormalities of Peripheral Blood T Lymphocytes and Natural Killer Cells in Alcoholic Hepatitis Persist after a 3-Month Withdrawal Period. Alcoholism: Clinical and Experimental Research, 1997, 21, 672-676.	1.4	28
119	Improved SÃ©zary cell detection and novel insights into immunophenotypic and molecular heterogeneity in SÃ©zary syndrome. Blood, 2021, 138, 2539-2554.	0.6	28
120	Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome. Brain Pathology, 2021, 31, 365-380.	2.1	27
121	Frequent issues and lessons learned from EuroFlow QA. Journal of Immunological Methods, 2019, 475, 112520.	0.6	26
122	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia, 2020, 34, 3007-3018.	3.3	26
123	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research, 2021, 27, 5195-5212.	3.2	26
124	Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. Frontiers in Oncology, 2019, 9, 449.	1.3	25
125	Evaluation of homo- and hetero-functionally activated glass surfaces for optimized antibody arrays. Analytical Biochemistry, 2014, 450, 37-45.	1.1	24
126	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBioMedicine, 2017, 26, 17-24.	2.7	24

#	Article	IF	Citations
127	Richter transformation driven by Epsteinâ€“Barr virus reactivation during therapyâ€related immunosuppression in chronic lymphocytic leukaemia. Journal of Pathology, 2018, 245, 61-73.	2.1	24
128	Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS Canto II, Navios and BD FACS Lyric instruments. Journal of Immunological Methods, 2019, 475, 112680.	0.6	24
129	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. Blood, 2020, 135, 2375-2387.	0.6	24
130	Intratumoral patterns of clonal evolution in gliomas. Neurogenetics, 2010, 11, 227-239.	0.7	23
131	How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. Journal of Immunological Methods, 2019, 475, 112388.	0.6	23
132	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. Journal of Allergy and Clinical Immunology, 2020, 146, 300-306.	1.5	23
133	Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality. Oncotarget, 2015, 6, 42938-42951.	0.8	23
134	Longâ€term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study. British Journal of Haematology, 1992, 82, 671-675.	1.2	22
135	Report on the first Latin American consensus conference for flow cytometric immunophenotyping of leukemia. Cytometry, 1998, 34, 39-42.	1.8	21
136	Peripheral Blood Dendritic Cell Subsets from Patients with Monoclonal Gammopathies Show an Abnormal Distribution and Are Functionally Impaired. Oncologist, 2008, 13, 82-92.	1.9	21
137	Ex vivo identification and characterization of a population of CD13high CD105+ CD45â^' mesenchymal stem cells in human bone marrow. Stem Cell Research and Therapy, 2015, 6, 169.	2.4	21
138	Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. Leukemia, 2019, 33, 1256-1267.	3.3	20
139	Lot-to-lot stability of antibody reagents for flow cytometry. Journal of Immunological Methods, 2019, 475, 112294.	0.6	20
140	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1953-1963.	2.0	20
141	Two new 3?PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. , 2000, 27, 35-43.		19
142	Expression profile of novel cell surface molecules on different subsets of human peripheral blood antigen-presenting cells. Clinical and Translational Immunology, 2016, 5, e100.	1.7	19
143	Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications. Cytometry Part B - Clinical Cytometry, 2017, 92, 361-370.	0.7	19
144	Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia. Leukemia, 2018, 32, 2701-2705.	3.3	19

#	Article	IF	Citations
145	Detection of Circulating Tumor Plasma Cells in Monoclonal Gammopathies: Methods, Pathogenic Role, and Clinical Implications. Cancers, 2020, 12, 1499.	1.7	19
146	Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. Journal of Allergy and Clinical Immunology, 2022, 149, 1855-1865.	1.5	19
147	Cellâ€cycle distribution of different cell compartments in normal versus reactive bone marrow: A frame of reference for the study of dysplastic hematopoiesis. Cytometry Part B - Clinical Cytometry, 2011, 80B, 354-361.	0.7	18
148	Impact of Next-Generation Flow (NGF) Minimal Residual Disease (MRD) Monitoring in Multiple Myeloma (MM): Results from the Pethema/GEM2012 Trial. Blood, 2017, 130, 905-905.	0.6	18
149	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDSâ€Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	0.7	18
150	Discrepancies Between Morphologic, Cytochemical, and Immunologic Characteristics in Acute Myeloblastic Leukemia. American Journal of Clinical Pathology, 1987, 88, 38-42.	0.4	17
151	Evaluation of a CD61 MoAb method for enumeration of platelets in thrombocytopenic patients and its impact on the transfusion decision-making process. Transfusion, 2001, 41, 1212-1216.	0.8	17
152	Selection and validation of antibody clones against IgG and IgA subclasses in switched memory B-cells and plasma cells. Journal of Immunological Methods, 2019, 475, 112372.	0.6	17
153	EuroFlow Standardized Approach to Diagnostic Immunopheneotyping of Severe PID in Newborns and Young Children. Frontiers in Immunology, 2020, 11, 371.	2.2	17
154	Highly Sensitive Flow Cytometry Allows Monitoring of Changes in Circulating Immune Cells in Blood After Tdap Booster Vaccination. Frontiers in Immunology, 2021, 12, 666953.	2.2	17
155	Anti-TRBC1 Antibody-Based Flow Cytometric Detection of T-Cell Clonality: Standardization of Sample Preparation and Diagnostic Implementation. Cancers, 2021, 13, 4379.	1.7	17
156	Integration of Proteomics and Transcriptomics Data Sets for the Analysis of a Lymphoma B-Cell Line in the Context of the Chromosome-Centric Human Proteome Project. Journal of Proteome Research, 2015, 14, 3530-3540.	1.8	16
157	COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2083-2086.	2.0	16
158	Association between Genetic Subgroups of Pancreatic Ductal Adenocarcinoma Defined by High Density 500 K SNP-Arrays and Tumor Histopathology. PLoS ONE, 2011, 6, e22315.	1.1	16
159	Flow cytometric analysis of myelodysplasia: Preâ€analytical and technical issuesâ€”Recommendations from the European <scp>LeukemiaNet</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	0.7	16
160	Identification and characterization of the gene expression profiles for protein coding and non-coding RNAs of pancreatic ductal adenocarcinomas. Oncotarget, 2015, 6, 19070-19086.	0.8	15
161	Complete Multilineage CD4 Expression Defect Associated With Warts Due to an Inherited Homozygous CD4 Gene Mutation. Frontiers in Immunology, 2019, 10, 2502.	2.2	15
162	Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study. Modern Pathology, 2021, 34, 59-69.	2.9	15

#	Article	IF	Citations
163	Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact. Cancers, 2021, 13, 4451.	1.7	15
164	Flow Cytometry in Mastocytosis. Immunology and Allergy Clinics of North America, 2014, 34, 297-313.	0.7	14
165	Delineating Human B Cell Precursor Development With Genetically Identified PID Cases as a Model. Frontiers in Immunology, 2019, 10, 2680.	2.2	14
166	Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML. American Journal of Clinical Pathology, 2015, 144, 484-492.	0.4	13
167	A pediatric regimen for adolescents and young adults with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. Cancer Medicine, 2020, 9, 2317-2329.	1.3	13
168	Heterogeneous EGFR, CDK4, MDM4, and PDGFRA Gene Expression Profiles in Primary GBM: No Association with Patient Survival. Cancers, 2020, 12, 231.	1.7	13
169	Dissection of the Pre-Germinal Center B-Cell Maturation Pathway in Common Variable Immunodeficiency Based on Standardized Flow Cytometric EuroFlow Tools. Frontiers in Immunology, 2020, 11, 603972.	2.2	13
170	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. American Journal of Human Genetics, 2021, 108, 284-294.	2.6	12
171	Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. Cancers, 2021, 13, 3900.	1.7	12
172	Improved Standardization of Flow Cytometry Diagnostic Screening of Primary Immunodeficiency by Software-Based Automated Gating. Frontiers in Immunology, 2020, 11, 584646.	2.2	11
173	Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. Journal of Molecular Diagnostics, 2020, 22, 679-684.	1.2	11
174	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. HemaSphere, 2021, 5, e536.	1.2	11
175	Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma. Cancers, 2021, 13, 4924.	1.7	11
176	Monocytes carrying GFAP detect glioma, brain metastasis and ischaemic stroke, and predict glioblastoma survival. Brain Communications, 2021, 3, fcaa215.	1.5	11
177	Age and Primary Vaccination Background Influence the Plasma Cell Response to Pertussis Booster Vaccination. Vaccines, 2022, 10, 136.	2.1	11
178	Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study. Cancers, 2022, 14, 1583.	1.7	11
179	Mastocytosis presenting with mast cellâ€mediator releaseâ€associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features. Clinical and Translational Allergy, 2022, 12, e12132.	1.4	11
180	Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. Cancers, 2021, 13, 1454.	1.7	10

#	Article	IF	Citations
181	Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts. , 2021, 9, e001514.		10
182	High-Sensitive TRBC1-Based Flow Cytometric Assessment of T-Cell Clonality in TÎ±Î²-Large Granular Lymphocytic Leukemia. Cancers, 2022, 14, 408.	1.7	10
183	Effect of Ethanol Consumption on Adult Rat Liver Mitochondrial Populations Analyzed by Flow Cytometry. Alcoholism: Clinical and Experimental Research, 1995, 19, 1327-1330.	1.4	9
184	Immune reconstitution in patients with Fanconi anemia after allogeneic bone marrow transplantation. Cytotherapy, 2014, 16, 976-989.	0.3	9
185	Maturationâ€associated gene expression profiles along normal human bone marrow monopoiesis. British Journal of Haematology, 2017, 176, 464-474.	1.2	9
186	Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: implications for disease progression. Haematologica, 2017, 102, 1238-1246.	1.7	9
187	Prognostic impact of a novel gene expression profile classifier for the discrimination between metastatic and non-metastatic primary colorectal cancer tumors. Oncotarget, 2017, 8, 107685-107700.	0.8	9
188	Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy. Modern Pathology, 2018, 31, 1318-1331.	2.9	9
189	Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis. International Journal of Molecular Sciences, 2019, 20, 552.	1.8	9
190	Tracking the Antibody Immunome in Sporadic Colorectal Cancer by Using Antigen Self-Assembled Protein Arrays. Cancers, 2021, 13, 2718.	1.7	9
191	Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial. Blood, 2015, 126, 1333-1333.	0.6	9
192	Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study. Blood Advances, 2021, , .	2.5	9
193	Genomic profiling of sporadic liver metastatic colorectal cancer. Seminars in Cancer Biology, 2021, 71, 98-108.	4.3	8
194	Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis. Blood, 2022, 139, 572-583.	0.6	8
195	Altered neutrophil immunophenotypes in childhood B-cell precursor acute lymphoblastic leukemia. Oncotarget, 2016, 7, 24664-24676.	0.8	8
196	Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. Cancers, 2021, 13, 5134.	1.7	8
197	Deepening into Intracellular Signaling Landscape through Integrative Spatial Proteomics and Transcriptomics in a Lymphoma Model. Biomolecules, 2021, 11, 1776.	1.8	8
198	Flow cytometric minimal residual disease assessment in Bâ€cell precursor acute lymphoblastic leukaemia patients treated with CD19â€targeted therapies â€" a EuroFlow study. British Journal of Haematology, 2022, 197, 76-81.	1.2	8

#	Article	IF	Citations
199	Cytogenetic heterogeneity of pancreatic ductal adenocarcinomas: identification of intratumoral pathways of clonal evolution. Histopathology, 2011, 58, 486-497.	1.6	7
200	Frequency of clonal mast cell diseases among patients presenting with anaphylaxis: A prospective study in 178 patients from 5 tertiary centers in Spain. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2924-2926.e1.	2.0	7
201	High frequency of chronic lymphocytic leukemia-like low-count monoclonal B-cell lymphocytosis in Japanese descendants living in Brazil. Haematologica, 2020, 105, e298-e301.	1.7	7
202	A systematic approach for peptide characterization of B-cell receptor in chronic lymphocytic leukemia cells. Oncotarget, 2017, 8, 42836-42846.	0.8	7
203	Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma. Archives of Pathology and Laboratory Medicine, 2022, 146, 862-871.	1.2	7
204	Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints. Blood, 2021, 138, 76-76.	0.6	7
205	Molecular profiling refines minimal residual diseaseâ€based prognostic assessment in adults with Philadelphia chromosomeâ€negative Bâ€cell precursor acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2019, 58, 815-819.	1.5	6
206	The poor prognosis of low hypodiploidy in adults with Bâ€cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. British Journal of Haematology, 2019, 186, 263-268.	1.2	6
207	Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia. British Journal of Haematology, 2021, 193, 922-927.	1.2	6
208	B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients. Cancers, 2021, 13, 1704.	1.7	6
209	Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.. Journal of Clinical Oncology, 2021, 39, 8010-8010.	0.8	6
210	Accurate apoptosis measurement requires quantification of loss of expression of surface antigens and cell fragmentation. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2006, 69A, 240-248.	1.1	5
211	Flow Cytometry Immunophenotyping for Diagnostic Orientation and Classification of Pediatric Cancer Based on the EuroFlow Solid Tumor Orientation Tube (STOT). Cancers, 2021, 13, 4945.	1.7	5
212	Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders. Annals of Allergy, Asthma and Immunology, 2021, 127, 427-434.	0.5	5
213	Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles. Oncotarget, 2018, 9, 28083-28102.	0.8	5
214	Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas. Frontiers in Oncology, 2021, 11, 740782.	1.3	5
215	Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis. Haematologica, 2011, 96, e26-e26.	1.7	4
216	Dynamic Intracellular Metabolic Cell Signaling Profiles During Ag-Dependent B-Cell Differentiation. Frontiers in Immunology, 2021, 12, 637832.	2.2	4

#	Article	IF	Citations
217	GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness. Blood, 2021, 138, 1590-1602.	0.6	4
218	Next Generation Flow (NGF): A High Sensitive Technique to Detect Circulating Peripheral Blood (PB) Clonal Plasma Cells (cPC) in Patients with Newly Diagnosed of Plasma Cell Neoplasms (PCN). Blood, 2015, 126, 4180-4180.	0.6	4
219	Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid. Cancers, 2022, 14, 449.	1.7	4
220	Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis. Cancers, 2022, 14, 2487.	1.7	4
221	Altered innate immune profile in blood of systemic mastocytosis patients. Clinical and Translational Allergy, 2022, 12, .	1.4	4
222	Altered Interphase Fluorescence in Situ Hybridization Profiles of Chromosomes 4, 8q24, and 9q34 in Pancreatic Ductal Adenocarcinoma Are Associated with a Poorer Patient Outcome. Journal of Molecular Diagnostics, 2014, 16, 648-659.	1.2	3
223	Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR. Frontiers in Oncology, 2020, 10, 611021.	1.3	3
224	Outcomes and prognostic factors of adults with refractory or relapsed Tâ€cell acute lymphoblastic leukemia included in measurable residual diseaseâ€oriented trials. Hematological Oncology, 2021, 39, 529-538.	0.8	3
225	Two new 3â€² PML Breakpoints in t(15;17)(q22;q21)â€positive acute promyelocytic leukemia. Genes Chromosomes and Cancer, 2000, 27, 35-43.	1.5	3
226	Detection of circulating tumor cells in blood of pancreatic ductal adenocarcinoma patients. Cancer Drug Resistance (Alhambra, Calif), 2020, 3, 83-97.	0.9	3
227	Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels. Cancers, 2022, 14, 473.	1.7	3
228	Quality Assessment of a Large Multi-Center Flow Cytometric Dataset of Acute Myeloid Leukemia Patientsâ€"A EuroFlow Study. Cancers, 2022, 14, 2011.	1.7	3
229	Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome. Cancers, 2022, 14, 3088.	1.7	3
230	EuroFlow and its activities: Introduction to the special EuroFlow issue of The Journal of Immunological Methods. Journal of Immunological Methods, 2019, 475, 112704.	0.6	2
231	Prognostic heterogeneity of adult Bâ€cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3â€PBX1 treated with measurable residual diseaseâ€oriented protocols. British Journal of Haematology, 2021, , .	1.2	2
232	Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Blood, 2015, 126, 367-367.	0.6	2
233	Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials. Blood, 2021, 138, 3486-3486.	0.6	2
234	Research update for articles published in EJCI in 2012. European Journal of Clinical Investigation, 2014, 44, 1010-1023.	1.7	1

#	Article	IF	Citations
235	High-throughgput phage-display screening in array format. Enzyme and Microbial Technology, 2015, 79-80, 34-41.	1.6	1
236	Neoplasias of dentritic cells: are they the counterpart of one or more cell lineages?. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2004, 10, 171.	1.2	1
237	The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. Frontiers in Oncology, 2021, 11, 723722.	1.3	0
238	Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials. Blood, 2020, 136, 6-7.	0.6	0